Mayo Clinic Platform

AccurKardia is a diagnostics software company specializing in ECG-led technology aimed at enhancing patient outcomes and saving lives worldwide. The company's flagship product, AccurECG™, is a cloud-based, FDA-cleared software that enables fully automated, near real-time interpretation of ECG data. AccurKardia has developed additional solutions, including AK+ Guard™, an AI-driven tool for early detection of hyperkalemia using Lead I ECG data, which has received FDA Breakthrough Device Designation. The company also created the AK-AVS™ model for aortic stenosis detection, which similarly attained Breakthrough Device Designation. AccurKardia's innovative platform combines proprietary artificial intelligence with traditional techniques to deliver clinical-grade ECG analytics, assisting cardiac monitoring companies in analyzing ECGs from various devices. The company has participated in notable accelerator programs, including the 2024 Cohort of MedTech Innovator and the American Heart Association’s Heart and Brain Health Accelerator track, further establishing its commitment to advancing cardiovascular health technology.

Saigeware, founded in 2020 and headquartered in Karnataka, India, specializes in developing an AI-based healthcare platform that supports evidence-based medicine, particularly in cardiac and pulmonary practices. The company's offerings include telemedicine services, drug discovery, and the design of original equipment manufacturers (OEMs), as well as personal wellness applications. By providing actionable insights, Saigeware aims to enhance the decision-making capabilities of healthcare professionals and improve patient outcomes across various health issues.

SOAP Health is a healthcare technology company based in Boca Raton, Florida, founded in 2019. It develops an artificial intelligence-powered platform designed to enhance physician productivity and improve patient outcomes. The platform captures and analyzes detailed patient data before medical visits and integrates with electronic health records to streamline clinical practice. By utilizing a conversational interface, it simplifies patient-reported data collection and risk assessment, producing nearly complete SOAP notes to assist physicians in clinical decision-making. This approach not only helps identify at-risk patients and facilitates early disease detection but also aims to increase patient engagement and satisfaction while reducing errors and liability exposure for healthcare providers.

Biotia, Inc. is a health tech company based in New York, founded in 2016. It specializes in developing software and laboratory technology that leverage next-generation DNA sequencing and artificial intelligence to enhance infectious disease discovery. Biotia's solutions focus on microbial surveillance and tailored sequencing to reduce hospital-acquired infections. By enabling clinicians and researchers to identify and stop pathogens before patients fall ill, Biotia aims to improve patient treatment and health outcomes, thereby contributing to safer healthcare environments.

Dynocardia, Inc. is a biomedical device company based in Massachusetts that specializes in wireless blood pressure measurement equipment. Founded in 2018, the company has developed a wrist-wearable device called ViTrack, which allows users to accurately and continuously measure vital health parameters, including blood pressure, heart rate, heart rhythm, and respiration rate. Utilizing an innovative optomechanical sensor, Dynocardia's technology offers a non-invasive method for blood pressure measurement, rivaling the accuracy of traditional intra-arterial measurements. The company's focus is on addressing critical unmet healthcare needs, providing a mobile, user-friendly solution for monitoring cardiovascular health.

Delfina is a company that specializes in developing a personalized prenatal care system aimed at ensuring the safety of mothers and infants during pregnancy. By leveraging data and machine learning, Delfina's platform creates individualized pregnancy care plans that assess patient risk through various metrics. This approach not only enhances interventional workflows but also improves provider efficiency, facilitating early intervention in prenatal care. Delfina's commitment to data-driven insights is paving the way for clinical innovation, ultimately striving to deliver equitable and cost-effective healthcare solutions for expectant families.

ImpriMed, Inc. is a company that specializes in drug testing services, focusing on the responses of live cancer cells from pets, particularly those with lymphoma. Based in Palo Alto, California, with a branch office in Seoul, South Korea, ImpriMed uses individualized drug response prediction technology to assist veterinary oncologists in selecting appropriate anticancer treatments. By collecting genetic and cellular information from pet cancer cells, the company creates a patient-derived database that not only aids in veterinary oncology but also holds potential for applications in human cancer care. This data-driven approach enables veterinarians to make informed decisions on final treatment regimens, ultimately enhancing precision medicine in both animal and human oncology. ImpriMed was incorporated in 2017.